Evidence map›Paper›PMID 41228221›Full record

ArticleCancers2025

Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate Cancer.

Soumaya Labidi, Belinda Jiao, Shirley Tam, Parvaneh Fallah, Aida Salehi, Raghu Rajan, Mona Alameldin, Fadi Brimo, William D Foulkes, Andreas I Papadakis and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Soumaya LabidiGerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Belinda JiaoGerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.ORCID 0009-0004-5427-5963
Shirley TamGerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Parvaneh FallahGerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.ORCID 0000-0001-7885-2009
Aida SalehiSegal Cancer Center, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
Raghu RajanGerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Mona AlameldinDepartment of Pathology, McGill University, Montreal, QC H3T 1E2, Canada.
Fadi BrimoDepartment of Pathology, McGill University, Montreal, QC H3T 1E2, Canada.
William D FoulkesDepartment of Human Genetics, School of Biomedical Sciences, McGill University, Montreal, QC H3A 1Y2, Canada.
Andreas I PapadakisSegal Cancer Center, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.ORCID 0000-0003-0026-6581
Nabodita KaulSegal Cancer Center, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
Alan SpatzGerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.ORCID 0000-0003-3020-1420
Cristiano FerrarioGerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Ramy R SalehGerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.ORCID 0000-0001-8265-9316
April A N RoseGerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.

Funding

Marathon of Hope Cancer Centers Network (MOHCCN) n/aPfizer (Canada) n/a
6 · The paper itself

Abstract

backgroundMetastatic prostate cancers frequently harbour pathogenic aberrations in Homologous Recombination Repair (HRR) genes that confer sensitivity to PARP inhibitors (PARPi). Therefore, accurate identification of all eligible patients is needed. The development of a circulating tumour DNA (ctDNA) testing alternative is promising as genomic testing of archived tissue leads to a failure rate of up to 30-40% in prostate cancer.

methodsThis was a bi-institutional retrospective cohort study of patients with metastatic prostate cancer treated at the Jewish General Hospital or the McGill University Health Center, Montreal, Canada, between 2021 and 2023. Molecular data and treatment information were abstracted from a chart review. Chi-square, Fisher's exact test, and Mann-Whitney tests were used to assess differences between groups.

resultsWe identified 484 metastatic prostate cancer patients. Somatic and germline testing for HRR was performed in 55.4% (

conclusionsThese data highlight a potential role in implementing liquid biopsy-especially in patients who only have older archival tissue available or failed tissue testing-to improve the detection rate of deficient HRR. Our ongoing prospective study will further validate whether the addition of liquid biopsy can identify more patients who are eligible to receive precision therapies by increasing the rate of detection of HRR deficiency compared to routine tissue testing alone.

Indexed as

ctDNAgermlineHRRliquid biopsyprostate cancersomatic

Identifiers

PMID41228221
PMCPMC12611088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.